CU24314B1 - Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos - Google Patents

Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos

Info

Publication number
CU24314B1
CU24314B1 CUP2015000171A CU20150171A CU24314B1 CU 24314 B1 CU24314 B1 CU 24314B1 CU P2015000171 A CUP2015000171 A CU P2015000171A CU 20150171 A CU20150171 A CU 20150171A CU 24314 B1 CU24314 B1 CU 24314B1
Authority
CU
Cuba
Prior art keywords
growth factor
fusion proteins
fibroblast growth
metabolic disorders
include useful
Prior art date
Application number
CUP2015000171A
Other languages
English (en)
Spanish (es)
Other versions
CU20150171A7 (es
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150171A7 publication Critical patent/CU20150171A7/es
Publication of CU24314B1 publication Critical patent/CU24314B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CUP2015000171A 2011-09-26 2012-09-26 Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos CU24314B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders

Publications (2)

Publication Number Publication Date
CU20150171A7 CU20150171A7 (es) 2016-07-29
CU24314B1 true CU24314B1 (es) 2018-02-08

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
CUP2015000171A CU24314B1 (es) 2011-09-26 2012-09-26 Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos
CUP2014000034A CU24206B1 (es) 2011-09-26 2014-03-26 Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2014000034A CU24206B1 (es) 2011-09-26 2014-03-26 Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos

Country Status (41)

Country Link
US (5) US9006400B2 (ja)
EP (2) EP2760475B1 (ja)
JP (4) JP6186361B2 (ja)
KR (1) KR102085605B1 (ja)
CN (2) CN107266579B (ja)
AP (1) AP2014007543A0 (ja)
AR (2) AR088044A1 (ja)
AU (1) AU2012316052A1 (ja)
BR (1) BR112014007069B1 (ja)
CA (1) CA2849464C (ja)
CL (2) CL2014000736A1 (ja)
CO (1) CO6920257A2 (ja)
CR (1) CR20140140A (ja)
CU (2) CU24314B1 (ja)
CY (2) CY1120928T1 (ja)
DK (2) DK3321276T3 (ja)
EA (1) EA039633B1 (ja)
ES (2) ES2895080T3 (ja)
GT (1) GT201400055A (ja)
HK (1) HK1251238A1 (ja)
HR (2) HRP20211575T1 (ja)
HU (2) HUE039857T2 (ja)
IL (1) IL231533B (ja)
IN (1) IN2014DN02043A (ja)
JO (1) JO3476B1 (ja)
LT (2) LT3321276T (ja)
MA (1) MA35437B1 (ja)
MX (1) MX350273B (ja)
MY (1) MY166059A (ja)
PE (2) PE20141551A1 (ja)
PL (2) PL3321276T3 (ja)
PT (2) PT3321276T (ja)
RS (2) RS62341B1 (ja)
SG (2) SG10201602339XA (ja)
SI (2) SI2760475T1 (ja)
TN (1) TN2014000109A1 (ja)
TW (1) TWI593708B (ja)
UA (1) UA113856C2 (ja)
UY (2) UY34346A (ja)
WO (1) WO2013049247A1 (ja)
ZA (1) ZA201401700B (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299015B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP3597666A3 (en) 2011-07-01 2020-04-22 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR20150104579A (ko) 2012-12-27 2015-09-15 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
SG11201606018UA (en) 2014-01-24 2016-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) * 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
AU2015335603B2 (en) 2014-10-24 2020-04-30 Bristol-Myers Squibb Company Modified FGF-21 polypeptides and uses thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP6940479B2 (ja) 2015-08-03 2021-09-29 ノバルティス アーゲー Ｆｇｆ２１関連障害を処置する方法
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
BR112018073861A2 (pt) * 2016-05-20 2019-02-26 President And Fellows Of Harvard College métodos de terapia de genes para doenças e condições relacionadas com a idade
US11318186B2 (en) 2016-05-25 2022-05-03 Board Of Regents, The University Of Texas System Use of FGF21 in methods of increasing exocrine pancreatic secretion
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3047862A1 (en) 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
EP3596130A4 (en) * 2017-03-14 2020-12-30 Sunshine Lake Pharma Co., Ltd. DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
EP3619324A4 (en) 2017-05-05 2020-12-30 Trefoil Therapeutics, Inc. RECOMBINATED MODIFIED FIBROBLASTIC GROWTH FACTORS AND THEIR THERAPEUTIC USES
CN115109166A (zh) * 2017-11-24 2022-09-27 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111601613A (zh) * 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
EP3749683A4 (en) 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
MX2021000016A (es) 2018-07-03 2021-03-09 Bristol Myers Squibb Co Formulaciones de factor de crecimiento de fibroblastos (fgf-21).
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
EP4076454A1 (en) 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ATE446365T1 (de) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic Menschliches fgf-21 gen und genexpressionsprodukte
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
EP1743648B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Method for treating inflammation
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
PL1751184T3 (pl) * 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
SI1789442T1 (sl) * 2004-09-02 2010-01-29 Lilly Co Eli Proteinske mutante fibroblastnega rastnega faktorja 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
BRPI0919932A8 (pt) 2008-10-24 2018-02-06 Novartis Ag Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
SI3248610T1 (sl) * 2009-05-05 2024-03-29 Amgen Inc., Mutanti fgf21 in njihove uporabe
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
CN102939303A (zh) 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
EP2760475B1 (en) 2018-07-04
CU20150171A7 (es) 2016-07-29
CL2014000736A1 (es) 2014-10-03
UA113856C2 (xx) 2017-03-27
EP2760475A1 (en) 2014-08-06
CU20140034A7 (es) 2014-08-28
JP6567613B2 (ja) 2019-08-28
NZ622998A (en) 2016-07-29
JP2022058546A (ja) 2022-04-12
HUE055584T2 (hu) 2021-12-28
SG10201602339XA (en) 2016-05-30
CN103945871A (zh) 2014-07-23
HRP20181558T1 (hr) 2018-11-30
CR20140140A (es) 2014-07-15
CO6920257A2 (es) 2014-04-10
IL231533B (en) 2018-06-28
PL2760475T3 (pl) 2018-11-30
AU2012316052A1 (en) 2014-04-17
JP2020007314A (ja) 2020-01-16
ZA201401700B (en) 2015-01-28
CN103945871B (zh) 2017-04-26
CN107266579A (zh) 2017-10-20
EP3321276A2 (en) 2018-05-16
CU24206B1 (es) 2016-10-28
WO2013049247A1 (en) 2013-04-04
AR088044A1 (es) 2014-05-07
DK3321276T3 (da) 2021-10-25
US20130079500A1 (en) 2013-03-28
CL2016002215A1 (es) 2016-10-28
MX2014003677A (es) 2014-04-30
TW201326213A (zh) 2013-07-01
HUE039857T2 (hu) 2019-02-28
US9266935B2 (en) 2016-02-23
US11944664B2 (en) 2024-04-02
BR112014007069B1 (pt) 2020-12-15
ES2689762T3 (es) 2018-11-15
IN2014DN02043A (ja) 2015-05-15
BR112014007069A2 (pt) 2017-03-28
ES2895080T3 (es) 2022-02-17
EP3321276A3 (en) 2018-06-20
CY1124697T1 (el) 2022-07-22
MY166059A (en) 2018-05-22
TN2014000109A1 (en) 2015-07-01
EA039633B1 (ru) 2022-02-18
JP6186361B2 (ja) 2017-08-23
AP2014007543A0 (en) 2014-03-31
GT201400055A (es) 2017-09-28
MA35437B1 (fr) 2014-09-01
US20210386824A1 (en) 2021-12-16
HRP20211575T1 (hr) 2022-02-04
CY1120928T1 (el) 2019-12-11
UY39119A (es) 2021-04-30
US9006400B2 (en) 2015-04-14
PE20141551A1 (es) 2014-10-26
US11129874B2 (en) 2021-09-28
UY34346A (es) 2013-04-30
TWI593708B (zh) 2017-08-01
US20150166622A1 (en) 2015-06-18
SG11201400538QA (en) 2014-06-27
EA201490695A1 (ru) 2015-10-30
US10076554B2 (en) 2018-09-18
SI2760475T1 (sl) 2018-10-30
PE20181159A1 (es) 2018-07-19
DK2760475T3 (en) 2018-10-15
US20160193297A1 (en) 2016-07-07
HK1251238A1 (zh) 2019-01-25
CN107266579B (zh) 2022-07-12
EP3321276B1 (en) 2021-07-28
SI3321276T1 (sl) 2021-11-30
MX350273B (es) 2017-08-31
CA2849464C (en) 2024-01-30
RS57868B1 (sr) 2018-12-31
PT3321276T (pt) 2021-10-27
JO3476B1 (ar) 2020-07-05
LT3321276T (lt) 2021-11-10
RS62341B1 (sr) 2021-10-29
JP7339372B2 (ja) 2023-09-05
PL3321276T3 (pl) 2022-01-17
JP2018023370A (ja) 2018-02-15
JP2014534172A (ja) 2014-12-18
LT2760475T (lt) 2018-10-25
AR123908A2 (es) 2023-01-25
CA2849464A1 (en) 2013-04-04
IL231533A0 (en) 2014-04-30
KR102085605B1 (ko) 2020-03-06
PT2760475T (pt) 2018-10-25
US20180369332A1 (en) 2018-12-27
KR20140069250A (ko) 2014-06-09

Similar Documents

Publication Publication Date Title
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
TN2014000110A1 (en) Dual function proteins for treating metabolic disorders
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders